0001493152-23-016007.txt : 20230510 0001493152-23-016007.hdr.sgml : 20230510 20230509190222 ACCESSION NUMBER: 0001493152-23-016007 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230510 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001335105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202903526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-252430 FILM NUMBER: 23903785 BUSINESS ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 BUSINESS PHONE: 310 203 2902 MAIL ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 7 INC DATE OF NAME CHANGE: 20050803 424B5 1 form424b5.htm

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-252430

PROSPECTUS SUPPLEMENT

(To Prospectus Supplement dated September 20, 2021)

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Common Stock

This prospectus supplement amends, supplements and supersedes our prospectus supplement, dated September 20, 2021 (the “September 2021 Prospectus”), related to an At-the-Market Sales Agreement with WestPark Capital, Inc., dated as of September 20, 2021 (the “Sales Agreement”), and should be read together with the accompanying prospectus dated February 5, 2021.

Our shares of common stock are listed on the Nasdaq Capital Market under the symbol “LIXT.” The closing price of our shares of common stock on May 5, 2023 on the Nasdaq Capital Market was $0.57. Under the September 2021 Prospectus, we initially registered up to $10,000,000 of our shares of common stock for offer and sale pursuant to the Sales Agreement.

Effective May 9, 2023, we terminated the Sales Agreement. Between September 20, 2021, the date of the Sales Agreement, and May 9, 2023, we have not sold any securities under the Sales Agreement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is May 9, 2023.